Vijay K Ratcliffe Liam Lathi Net Worth

The estimated Net Worth of Vijay K Ratcliffe Liam Lathi is at least $406 Thousand dollars as of 30 May 2018. Vijay Lathi owns over 662,677 units of Iterum Therapeutics Plc stock worth over $405,769 and over the last 6 years Vijay sold ITRM stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Vijay Lathi ITRM stock SEC Form 4 insiders trading

Vijay has made over 1 trades of the Iterum Therapeutics Plc stock since 2018, according to the Form 4 filled with the SEC. Most recently Vijay bought 662,677 units of ITRM stock worth $8,614,801 on 30 May 2018.

The largest trade Vijay's ever made was buying 662,677 units of Iterum Therapeutics Plc stock on 30 May 2018 worth over $8,614,801. On average, Vijay trades about 662,677 units every 0 days since 2018. As of 30 May 2018 Vijay still owns at least 384,615 units of Iterum Therapeutics Plc stock.

You can see the complete history of Vijay Lathi stock trades at the bottom of the page.

What's Vijay Lathi's mailing address?

Vijay's mailing address filed with the SEC is Times Square Tower, New York, NY 10036, USA.

Insiders trading at Iterum Therapeutics Plc

Over the last 6 years, insiders at Iterum Therapeutics Plc have traded over $51,533,386 worth of Iterum Therapeutics Plc stock and bought 4,586,895 units worth $57,505,095 . The most active insiders traders include Capital Management, L.P.Ra ..., Alexander J Sarissa Capital..., and James Healy. On average, Iterum Therapeutics Plc executives and independent directors trade stock every 38 days with the average trade being worth of $474,585. The most recent stock trade was executed by Michael W. Dunne on 6 August 2024, trading 106,247 units of ITRM stock currently worth $112,091.

What does Iterum Therapeutics Plc do?

iterum therapeutics plc is an ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. these products are aimed at combatting the global crisis of multi-drug resistant (mdr) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. for more information on iterum therapeutics please visit www.iterumtx.com.

Complete history of Vijay Lathi stock trades at Iterum Therapeutics Plc

Iterum Therapeutics Plc executives and stock owners

Iterum Therapeutics Plc executives and other stock owners filed with the SEC include:

• Corey Fishman,
  Chief Executive Officer, Director
• Corey N. Fishman,
  Pres, CEO & Director
• Michael Dunne,
  Chief Scientific Officer
• Judith Matthews,
  Chief Financial Officer
• Judith M. Matthews,
  Chief Financial Officer
• Dr. Michael W. Dunne M.D.,
  Strategic Advisor & Director
• Dr. Sailaja Puttagunta M.D.,
  Chief Medical Officer
• Brenton Ahrens,
  Independent Interim Chairman of the board
• Shahzad Malik,
  Independent Director
• David Kelly,
  Independent Director
• Ronald Hunt,
  Independent Director
• Patrick Heron,
  Independent Director
• Mark Chin,
  Independent Director
• Dr. Steven I. Aronin M.D.,
  Sr. VP & Head of Clinical Devel.
• Louise Barrett,
  Sr. VP of Legal Affairs & Sec.
• Tom Loughman Ph.D.,
  Sr. VP of Technical Operations
• Beth Hecht,
  Director
• Vijay K Ratcliffe Liam Lathi,
  
• Venture Partners Ix, L.P.Po...,
  
• James Healy,
  Director
• X L.P.Canaan Partners X Llc...,
  
• Paul R Edick,
  Director
• Jeffrey R. Schaffnit,
  Chief Commercial Officer
• Patrick J Heron,
  Director
• Capital Management, L.P.Ra ...,
  
• Healthcare Vii, L.P.Frazier...,
  
• Venture Partners Ix, L.P.So...,
  
• Venture Partners Ix, L.P.So...,
  
• Alexander J Sarissa Capital...,
  
• Sailaja Puttagunta,
  Chief Medical Officer